MAAT For Young Adult Cancer Survivors

The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. Participants in this single-group pilot trial (N=9) will complete online self-report measures of cognitive symptoms, quality of life, treatment satisfaction and a brief online neuropsychological test battery at baseline and post-MAAT-YS timepoints.

Inclusion Criteria: 1. Adults aged 18-39 2. Diagnosed prior to 18 years of age with non-CNS solid tumor or leukemia/lymphoma without known CNS involvement 3. At least 1 year after completion of treatment including chemotherapy, cancer-free 4. English fluent 5. Memory or other cognitive problems attributed to cancer and/or cancer treatment 6. Score of \<10 on the FACT-Cog Impact on Quality of Life Scale 7. Willing to use telehealth with internet access 8. Willing to provide informed consent to participation Exclusion Criteria: 1. Severe non-cancer brain injury such as severe traumatic brain injury, stroke or toxic injury causing memory impairments; 2. Currently meeting Diagnostic and Statistical Manual-5 (DSM-5) criteria for a severe psychiatric disorder, including substance abuse, mood, anxiety, or psychotic disorders, as assessed by the PRIME-MD; 3. Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;59 4. Severe uncorrected sensory impairment (severe hearing or visual impairment).